{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nMiR-6126 plays a critical tumor‐suppressive role in ovarian cancer by modulating multiple aspects of tumor progression. It is abundantly secreted via exosomes from both chemosensitive and chemoresistant ovarian cancer cells, and its expression is higher in healthy ovarian tissue compared to cancerous samples—correlating with better overall survival in patients with high‐grade serous ovarian cancer. Functionally, miR-6126 directly targets integrin-β1, thereby reducing metastatic behaviors such as invasion, migration, and endothelial tube formation. Moreover, treatment with a miR-6126 mimic leads to decreased integrin-β1 mRNA levels in exosomes, diminished tumor growth, reduced proliferation, and lower microvessel density in vivo, while inhibition of miR-6126 promotes oncogenic behavior by increasing exosome release."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}, {"type": "p", "children": [{"type": "t", "text": "\nIn the context of chronic hepatitis B virus (HBV) infection, miR-6126 has emerged as a promising biomarker and therapeutic agent. During pegylated interferon therapy, elevated serum levels of miR-6126 at week 24 predict a sustained 1-log reduction in HBs antigen 48 weeks post-treatment. In vitro studies further support its antiviral activity; miR-6126 not only reduces HBsAg secretion into the culture medium but also decreases intracellular HBV-DNA levels, underlying its potential to suppress viral replication."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}]}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Pinar Kanlikilicer, Mohammed H Rashed, Recep Bayraktar, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Res (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/0008-5472.CAN-16-0714"}], "href": "https://doi.org/10.1158/0008-5472.CAN-16-0714"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27742688"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27742688"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Koji Fujita, Shima Mimura, Hisakazu Iwama, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Mol Sci (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3390/ijms19071940"}], "href": "https://doi.org/10.3390/ijms19071940"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "30004437"}], "href": "https://pubmed.ncbi.nlm.nih.gov/30004437"}]}]}]}